21 results on '"Paccone, A"'
Search Results
2. 36P Short-term immune check-point inhibitor treatment reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and serum IL-1, IL-2 and IL-6 levels.
3. OXIDIZED LOW-DENSITY LIPOPROTEIN EXACERBATES NIVOLUMAB-INDUCED CARDIOTOXICITY BY MODULATING TLR4/NF-KB AND NLRP3 PATHWAYS.
4. PCSK9 INHIBITOR EVOLOCUMAB REDUCES CARDIOTOXICITY OF DOXORUBICIN AND TRASTUZUMAB SEQUENTIAL TREATMENT THROUGH MYD88/NF-KB/MTORC1 PATHWAYS.
5. VERICIGUAT PREVENTS ANTHRACYCLINE-MEDIATED CARDIOTOXICITY AND SARCOPENIA THROUGH CGMP-NLRP3-CYTOKINE PATHWAY: POTENTIAL APPLICATION IN CANCER PATIENTS.
6. SEMAGLUTIDE EXERTS SIGNIFICANT CARDIOPROTECTIVE PROPERTIES AGAINST ANTHRACYCLINE AND TRASTUZUMAB INDUCED CARDIOTOXICITY: BIOCHEMICAL EVIDENCES.
7. COMBINATION THERAPY WITH SEMAGLUTIDE AND PCSK9I REDUCES SYNERGISTICALLY ANTHRACYCLINE-INDUCED CARDIOTOXICITY UNDER HYPERLIPIDEMIA: IMPLICATIONS IN PRIMARY PREVENTION OF CTRCD IN CANCER PATIENTS.
8. COMBINATION THERAPY WITH SEMAGLUTIDE AND VERICIGUAT AS AN EFFECTIVE PREVENTIVE THERAPY OF 5-FU INDUCED CARDIOTOXICITY IN CANCER PATIENTS: PRELIMINARY EVIDENCES IN CARDIO-ONCOLOGY.
9. 27P Oxidized low-density lipoprotein induces cell dead and inflammation in cardiomyocytes exposed to nivolumab by TLR4/NF-κB and NLRP3/myd88 pathways.
10. FRUCTOSE EXACERBATES ANTHRACYCLINE AND HER-2 BLOCKING AGENT MEDIATED CARDIOTOXICITY THROUGH NLRP3 AND MYD88 MEDIATED PATHWAYS: NEW ROLES OF SWEETENERS IN CARDIO-ONCOLOGY.
11. SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR DAPAGLIFLOZIN REDUCES SYSTEMIC H-FABP AND MONOCYTE-TO-LYMPHOCYTE RATIO IN PRECLINICAL MODELS OF ANTRACYCLINE INDUCED CARDIOTOXICITY.
12. COMBINATORIAL IMMUNE CHECKPOINT BLOCKADE INCREASES MYOCARDIAL SECRETION OF H-FABP, NT-PRO-BNP, NLRP-3 INFLAMMASOME, INTERLEUKIN-1β AND INTERLEUKIN-6: BIOCHEMICAL IMPLICATIONS IN CARDIO-IMMUNO-ONCOLOGY.
13. BERBERINE ASSOCIATED TO DAPAGLIFLOZIN EXERTS SIGNIFICANT CARDIOPROTECTIVE EFFECTS IN CARDIAC CELLS EXPOSED TO THE HER2-BLOKING AGENT TRASTUZUMAB THROUGH PAMPK ACTIVATION AND REDUCTION IN INTERLEUKIN-6 LEVELS.
14. Mastication induces long-term increases in blood perfusion of the trigeminal principal nucleus.
15. 15P The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR-α and NLRP3-related pathways.
16. 14P Sacubitril-valsartan increases pAMPK and reduces NLRP3, MyD88, interleukin-6 and galectin-3 in short-term doxorubicin-treated mice improving longitudinal strain and ejection fraction.
17. 13P Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, methylglyoxal and leukotrienes-B4 levels.
18. Interaction between aging and neurodegeneration in amyotrophic lateral sclerosis
19. DIFFERENTIAL CARDIOTOXICITY OF IMMUNE CHECKPOINT INHIBITORS INVOLVES DAMPS FIBRONECTIN-EDA, S100/CALGRANULIN, GALECTINE-3 AND ASSOCIATED NLRP3 INFLAMMASOMECHEMOKINE PATHWAY IN PRECLINICAL MODELS.
20. PALMITOYLETHANOLAMIDE-POLYDATIN COMPLEX REDUCES INFLAMMATION IN HUMAN VASCULAR ENDOTHELIAL CELLS EXPOSED SEQUENTIALLY TO DOXORUBICIN AND TRASTUZUMAB THROUGH LKB1-AMPK AND NLRP3-CYTOKINE RELATED PATHWAYS.
21. 6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.